Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case Report

Persistent respiratory failure after SARS-CoV-2 infection: The role of dual energy computed tomography. A case report

Silvia Menale, MDa,⁎, Valentina Scheggi, MDa, Jacopo Giovacchini, MDb, Niccolò Marchionni, MD, PhDb

aDivision of Cardiovascular and Perioperative Medicine, Cardiothoracic vascular Department Azienda Ospedaliero-Universitaria Careggi and Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50139, Italy
bDivision of General Cardiology, Careggi Hospital and Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50139, Italy

Abstract

Background: COVID-19 disease is often complicated by respiratory failure, developing through multiple pathophysiological mechanisms, with pulmonary embolism (PE) and microvascular thrombosis as key and frequent components. Newer imaging modalities such as dual-energy computed tomography (DECT) can represent a turning point in the diagnosis and follow-up of suspected PE during COVID-19. Case presentation: A 78-year-old female presented to our internal medicine 3 weeks after initial hospitalization for COVID-19 disease, for recrudescent respiratory failure needing oxygen therapy. A computed tomography (CT) lungs scan showed a typical SARS-CoV-2 pneumonia. Over the following 15 days, respiratory function gradually improved. Unexpectedly, after 21 days from symptom onset, the patient started complaining of breath shortening with remarkable desaturation requiring high-flow oxygen ventilation. CT pulmonary angiography and transthoracic echocardiography were negative for signs of PE. Thereby, Dual-energy CT angiography of the lungs (DECT) was performed and detected diffuse peripheral microembolism. After 2 weeks, a second DECT was performed, showing a good response to the anticoagulation regimen, with reduced extent of microembolism and some of the remaining emboli partially recanalized. Discussion: DECT is an emerging diagnostic technique providing both functional and anatomical information. DECT has been reported to produce a much sharper delineation of perfusion defects than pulmonary scintigraphy, using a significantly lower equivalent dose of mSv. We highlight that DECT is particularly useful in SARS-CoV-2 infection, in order to determine the predom-
Introduction

Progressive respiratory failure is a major cause of death in COVID-19 disease [1]. The underlying pathophysiologic mechanism leading to respiratory failure is multifactorial including, beyond inflammation, endothelial damage, intussusceptive angiogenesis, and microvascular thrombosis [1,2] On the other hand, the diagnosis of pulmonary embolism (PE) or thrombo sis may be sometimes difficult, and the most used tools cannot always exclude this diagnostic suspicion, because microembolization or in situ thrombosis in the most peripheral regions of the lung are difficult to be detected. In front of such a challenging diagnostic scenario, dual-energy computed tomography (DECT), may result more informative and, hence, clinically helpful. In fact, DECT can produce a detailed definition of both morphology and perfusion in a single spiral image with secondary iodine maps using 2 X-ray energy spectra, high and low kilovoltage [3,4].

Case presentation

We report here the case of a 78-year-old woman who developed an acute respiratory insufficiency 1 month after hospitalization for SARS-CoV-2-related pneumonia.

Her past medical history included arterial hypertension, chronic bronchitis, and chronic hepatitis C virus infection. Previous invasive procedures included appendectomy and right carpal tunnel surgery. She had presented to the emergency department because of increasing shortness of breath and fever up to 37.5°C in the last 5 days. The molecular swab test was positive for SARS-CoV-2. The patient was alert and oriented; the respiratory rate was slightly increased to 20/min. Arterial blood gases analysis revealed mild hypoxia with respiratory alkalosis (pH 7.46, pCO₂ 37.7 mm Hg, PO₂ 71 mm Hg, SPO₂ 95% with FiO₂ 21%). Chest ultrasound showed normal pleural sliding bilaterally, B-lines up to 6-7 on examination, and no pleural effusion. At chest radiography, disseminated areas of increased density in the lung parenchyma were detected. After initial triage, she was admitted to the division of infectious disease, where she was treated with intravenous steroids (methylprednisolone 60 mg die), LMWH at a prophylactic dose and oxygen therapy (FiO₂ 36%-50%). A computed tomography (CT) lungs scan showed a relevant thickening of the parenchyma and bilateral ground-glass opacities, predominately in peripheral and posterior regions, with overall typical aspects of SARS-CoV-2 pneumonia. Echocardiography demonstrated a preserved left ventricular systolic function and moderate aortic valve regurgitation, without signs of pulmonary hypertension.

Over the following 10 days, respiratory function gradually improved until almost complete weaning from O₂ therapy. Unexpectedly, 21 days after symptom onset, the patient started complaining of breath shortening with relevant desaturation (SpO₂ 87%), associated with chest tightness, requiring high-flow nasal cannula oxygen delivery (40 l/min with 60% FiO₂).

A pulmonary CT angiography excluded a new-onset PE or progression of viral-related pneumonia. A subsequent DECT detected, at iodine perfusion maps, multiple triangular peripheral focal areas of hypoperfusion that were consistent with diffuse microembolism (Figs. 1 and 2).

LMWH therapy was then increased to an anticoagulant dosage. The respiratory profile remained stable with 50% FiO₂. Meanwhile, the patient tested negative for SARS-CoV-2 at a control swab and was moved to our division of internal medicine.

On admission, laboratory data showed normal haematocrit and inflammatory markers, with persistently high D-dimer levels (1217 ng/mL), while liver and cardiac enzymes, and renal function were normal. The patient still needed the same ventilatory support, with moderate hypoxemia and respiratory alkalosis at hemogasanalysis (pH 7.30, PO₂ 57 mm Hg, pCO₂ 31 mm Hg). After three weeks from admission to our division, a second DECT was performed, showing a good response to the anticoagulation regimen translating into a reduced extension of microemboli, with some of the remaining ones that were partially recanalized. A medium-dose corticosteroids and oxygen therapy were maintained, combined with respiratory physiotherapy and daily periods of pronation. The patient’s general condition and respiratory function gradually improved, requiring only a small amount of oxygen support at discharge. A further, 3-month contrast-enhanced chest CT control, showed almost complete peripheral vessels recanalization and reduced areas of parenchymal consolidation (Fig. 3).

Discussion

A series of specific events correlated with disease severity have been observed to contribute to the procoagulant state in COVID-19 disease: direct and indirect endothelial damage with activation of the coagulation pathway, platelet activation, complement and immune activation with the onset of an inflammatory cytokine storm involving IL2, IL6, MCP-1, MIP-1A, and TNF-α [5,6]. This process, termed immunothrombosis, complements other additional risk factors (high ferritin, elevated antiphospholipid antibodies, obesity) and the classic venous thromboembolism pathways that characterise COVID-19 [2,6].

Moreover, inflammation-induced endothelial cell dysfunction leads to an increased release of von Willebrand factor (vWF) multimers, triggering thrombotic microangiopathy [7]. ADAMTS-13 levels and ultra-large vWF multimers in patients
with sepsis is inversely correlated, as several studies asserted. More recently, Bazzan et al. reported significantly reduced ADAMTS-13 levels in a cohort of COVID-19 patients. They found that ADAMTS-13 levels below 30% of the normal values, combined with high plasma vWF levels, predicted an increased risk of death in COVID-19 [8].

Thrombotic events occur in more than 30% of patients with COVID-19 predominantly affecting the lungs, and are associated with more severe disease and higher mortality [1,5]. It is well known how SARS-CoV-2 favors the respiratory tract, where its entrance into target cells occurs through an angiotensin-converting enzyme 2 receptor, as well as in other organs such as the kidneys, heart, brain, and liver [2,5,6].

While PE has been detected in around 5%-14% of COVID-19 patients [9, 10], it is important to notice that such reported prevalence likely underestimated the real numbers of COVID-19-related PE, since CT pulmonary angiography (CTPA) has not been performed in all cases.

Indeed, in case of suspected PE, conventional CTPA is the first-line recommended diagnostic method. However, as highlighted by the clinical case we have described, its sensitivity in assessing the involvement of small-diameter (ie, subsegmental) pulmonary arteries is variable, and provides anatomical information only. An optimal definition of pulmonary artery subsegmental branches has been developed with the newest CT techniques, such as the combination with iodine map in the DECT method, providing both morphological and detailed functional information [11].

Therefore, when a PE of subsegmental segments is suspected because of prolonged respiratory distress despite reduced parenchymal inflammation, further imaging techniques are needed, with lung ventilation/perfusion scintigraphy or DECT as possible alternatives, with some difference.

DECT displays pulmonary perfusion defects in good agreement with perfusion scintigraphy [12], but provides more detailed high-quality images of the anatomy of pulmonary circulation. Indeed, analysis from the same datasets demonstrated what extension DECT was more accurate than perfusion scintigraphy in the detection of PE [13,14], and DECT provides a remarkably sharper delineation of perfusion defects with lower equivalent radiation [15].

Based on this evidence, our patient underwent first a conventional CTPA but then, because of the persistent respiratory failure, was further studied with DECT, in order to more accurately search for PE. In our clinical case, the choice to perform DECT rather than pulmonary scintigraphy was also related to a simpler and faster access to this diagnostic method, which is also well reproducible in the follow-up [15].
Fig. 2 – Iodine perfusion map-arterial phase. Focal-low perfusion zones with irregular and filiform arterial vessels, at lateral-basal segment of the inferior left pulmonary lobe.

Fig. 3 – pulmonary arterial phase, Chest CT. Complete vessel recanalization, perfusion defects are no longer noticeable.
DECT is an emerging imaging technique based on the acquisition of data using 2 X-ray energy spectra, high and low kilovoltage, within a single scan. In fact, if conventional single-energy examination CT produces only a single set of images, dual-energy data can be used to reconstruct numerous types of images, such as weighted average images, material decomposition images, and electron density mapping that allows structures with similar density to be distinguished according to their electron density differences [4]. Employment of an iodine-containing contrast agent improves the signal to noise ratio, and allows quantitative measurement of the contrast agent in the lungs through the generation of iodine maps as an indicator of pulmonary blood flow [16]. Tissue discrimination is based on differential attenuation of the radiation beam. Retro-reconstruction is then used to create a distribution map of the iodinated contrast agent, which allows us to examine and highlight conditions of the pulmonary circulation, even at the parenchymal level [16]. Iodine maps increase the specificity of PE detection as well, enabling a quantitative analysis of the volume of perfusion defect, thereby reducing false positivity and overdiagnosis [17]. It provides a pulmonary CT angiogram with high spatial resolution of small vessels and parenchyma at the same time, with no additional radiation exposure [12]. However, false-negative or false-positive results of DECT for perfusion or ventilation defects due to motion artefacts or excessive contrast must be considered as possible methodological limitations. Moreover, DECT its use is limited in morbidly obese patients because of the interference with structural and functional image analysis [18].

**Conclusions**

In summary, despite some abovementioned limitations, DECT can provide superior both anatomic and functional information in various lung diseases [19]. This tool is particularly useful in COVID-19 with marked or prolonged respiratory distress after first-line radiological thoracic examination, in order to determine the predominant underlying pathophysiology and, hence, individually tailor the therapeutic approach.

**Ethics approval and consent to participate**

Not applicable.

**Patient consent**

Written informed consent was obtained from the patient.

**Availability of data and materials**

Not applicable.

**REFERENCES**

[1] Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. New Engl J Med 2020;383(2):120–8. doi:10.1056/NEJMoA2015432.

[2] Henry BM, Vikse J, Benoit S, Favaloro BJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020;507:167–73. doi:10.1016/j.cca.2020.04.027.

[3] Furlow B. Dual-energy computed tomography. Radiol Technol 2015;86(3) 301ct-21ct; PMID: 25739115.

[4] Baerenda E, Smit CT, Das M, Sechopoulos I, Brink M, Oostveen LJ, Smit CT. Comparing dual energy CT and subtraction CT on a phantom: which one provides the best contrast in iodine maps for sub-centimetre details? Eur Radiol 2018;28(12):5051–9. doi:10.1007/s00330-018-5496-x.

[5] Loo J, Spittle DA, Newham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021;76(4):412–20. doi:10.1136/thoraxjnl-2020-216243.

[6] Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020;126(10):1456–67. doi:10.1161/CIRCRESAHA.120.317015.

[7] Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. Thromb Haemost 2018;16:646–51. doi:10.1111/jth.13953.

[8] Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med 2020;15(5):861–3. doi:10.1007/s11739-020-02394-0.

[9] Miró O, S Jiménez, Mebazaa A, Freund J, Burillo-Putze G, Martin A. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Eur Heart J 2021;42(33):3127–42. doi:10.1093/eurheartj/ehab314.

[10] Jevnikar M, Sanchez O, Chocron R, Andronikof M, Raphael M, Meyrignac O. Prevalence of pulmonary embolism in patients with COVID 19 at the time of hospital admission. Eur Respir J 2021. doi:10.1183/13993003.00116-2021.

[11] Lu GM, Wu SY, Yeh BM, Zhang LJ. Dual-energy computed tomography in pulmonary embolism. Br J Radiol 2010;83(992):707–18. doi:10.1259/bjr/16337436.

[12] Thieme SF, Becker CR, Hacker M, Nikolau K, Reiser MF, Johnson TR. Dual-energy CT for the assessment of lung perfusion–correlation to scintigraphy. Eur J Radiol 2008;68(3):369–74. doi:10.1016/j.ejrad.2008.07.031.

[13] Aran S, Besheli LD, Karcaaltincaba M, Gupta R, Abujudeh HH, Flores EJ. Applications of dual-energy CT in emergency radiology. AJR 2014;202:W314–24. doi:10.2214/AJR.13.11682.

[14] Masy M, Giordano J, Petyt G, Hossein-Foucher C, Kyheng M, lain Duhamel A. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018;28:5100–10. doi:10.1007/s00330-018-5467-2.

[15] Si-Mohamedab S, Morera-tribey C, Tylskid P, Tatard-Leitman V, Widowik Q, Boccalini S. Head-to-head comparison of lung perfusion with dual-energy CT and SPECT-CT: Diagn Interv Imaging 2020;101(5):299–310. doi:10.1016/j.diij.2020.02.006.
[16] McCollough CH, Leng S, Yu L, Fletcher JG. Dual- and multi-energy CT: principles, technical approaches, and clinical applications. Radiology 2015;276(3):637–53. doi: 10.1148/radiol.2015142631.

[17] Grob D, Smit E, Prince J, Kist J, Kist J, Stöger L. Iodine maps from subtraction CT or dual-energy CT to detect pulmonary emboli with CT angiography: a multiple-observer study. Radiology 2019;292(1):197–205. doi: 10.1148/radiol.2019182666.

[18] Masy M, Giordano J, Petyt G, Hossein-Foucher C, Duhamel A, Kyheng M, et al. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018;28(12):5100–10. doi: 10.1007/s00330-018-5467-2.

[19] Capone C, Valentini A, Spinillo S, Klersy C, Klersy C, Celentano A. Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2021;31(8):6230–8. doi: 10.1007/s00330-020-07558-4.